Search

Your search keyword '"Ueda, Yutaka"' showing total 2,317 results

Search Constraints

Start Over You searched for: Author "Ueda, Yutaka" Remove constraint Author: "Ueda, Yutaka"
2,317 results on '"Ueda, Yutaka"'

Search Results

4. Novel Strategy for the Management of Cervical Multicystic Diseases

5. Awareness of Infectious Disease Screening During Early Pregnancy and Knowledge About its Vertical Transmission in Japan: A Report from the Pregnant Women Health Initiative

10. Occupation switching of $d$ orbitals probed via hyperfine interactions in vanadium dioxide

11. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations

16. ASO Visual Abstract: Novel Strategy for the Management of Cervical Multicystic Diseases

24. Pressure-induced Superconductivity in the Iron-based Ladder Material BaFe2S3

25. Site-Selective Mott Transition in a Quasi-One-Dimensional Vanadate V6O13

26. Temperature and composition phase diagram in the iron-based ladder compounds Ba1-xCsxFe2Se3

27. Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.

28. Laparoscopic Radical Hysterectomy

30. Supplementary Figure legend from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

31. Supplementary Table 3 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

32. Supplementary Table 7 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

33. Supplementary Table 8 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

34. Supplementary Table 6 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

35. Data from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

36. Supplementary Figure 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

37. Supplementary Table 9 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

38. Supplementary Table 4 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

39. Supplementary Table 5 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

40. Supplementary Table 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

41. Supplementary Figure 1 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

42. Supplementary Table 2 from SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma

43. Suppressed pediatric asthma hospitalizations during the COVID‐19 pandemic in Japan, from a national survey

44. Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002)

Catalog

Books, media, physical & digital resources